Close Menu

NEW YORK – Rapid molecular testing for sexually transmitted infections has been on the horizon for two decades, and with US Food and Drug Administration clearance earlier this month of Binx Health's Binx io instrument and assay for chlamydia and gonorrhea, a new market opportunity may now have opened for many other tests and systems currently in development.

The clearance marks a milestone for one group in particular — Charlotte Gaydos and a point-of-care STI diagnostics development center she helped to establish at Johns Hopkins University.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.